Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Next Previous
Trial Profile

Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol/paclitaxel (Primary) ; Everolimus (Primary) ; Sirolimus (Primary) ; Umirolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms IRIS-DES

Most Recent Events

  • 12 Dec 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2030.
  • 12 Dec 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2030.
  • 01 Aug 2023 Planned number of patients changed from 18600 to 50000.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top